PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma

NCT06813976 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

294

Enrollment

OTHER

Sponsor class

Conditions

Ampullary Adenocarcinoma

Interventions

DRUG: mFOLFORINOX
DRUG: Capecitabine or gemcitabine
OTHER: Quality of life questionnaires: QLQ-C30 and PAN26
BIOLOGICAL: Biological assessment
DIAGNOSTIC_TEST: Paraclinical examinations

Sponsor

Centre Hospitalier Universitaire Dijon